Hoth Therapeutics Receives Patent for Exon Skipping and MS4A6A Modulation Approach.

Hoth Therapeutics announced that the USPTO has issued a Notice of Allowance for a patent covering a combination of FC Epsilon RI-Beta exon skipping and MS4A6A modulation. The patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses, positioning Hoth at the forefront of next-generation immunomodulatory therapies. The allowed claims cover methods directed at exon skipping a critical component of the high-affinity IgE receptor pathway central to allergic responses.